Navidea Biopharmaceuticals (NYSE:NAVB) Earns Sell Rating from Analysts at StockNews.com

Research analysts at StockNews.com initiated coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVBGet Rating) in a research note issued to investors on Monday. The firm set a “sell” rating on the stock.

Navidea Biopharmaceuticals Trading Up 1.1 %

Shares of NYSE:NAVB opened at $0.26 on Monday. The company has a fifty day simple moving average of $0.25 and a 200 day simple moving average of $0.51. The firm has a market cap of $8.36 million, a PE ratio of -0.46 and a beta of 1.36. Navidea Biopharmaceuticals has a 12-month low of $0.21 and a 12-month high of $1.38.

About Navidea Biopharmaceuticals

(Get Rating)

Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases.

See Also

Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.